Cover Image
Market Research Report

Partnerships, Licensing, Investments and M&A Deals and Trends for March 2017 in Pharmaceuticals

Published by GlobalData Product code 248823
Published Content info 78 Pages
Immediate Delivery Available
Price
Back to Top
Partnerships, Licensing, Investments and M&A Deals and Trends for March 2017 in Pharmaceuticals
Published: May 1, 2017 Content info: 78 Pages
Description

GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends for March 2017 in Pharmaceuticals" report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in March 2017. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData's proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.

Scope

  • Analysis of the market trends for the pharmaceutical industry in the global arena.
  • Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.
  • Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
  • Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
  • Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
  • Analysis of partnership and licensing deals based on clinical stage of development of products.
  • Summary of the pharmaceutical deals globally in the six months.
  • Information on the top deals happened in the pharmaceutical industry.
  • Geographies covered include - North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
  • League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to buy

  • Enhance your decision making capability in a more rapid and time sensitive manner.
  • Find out the major deal performing segments for investments in your industry.
  • Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
  • Identify companies that are aggressively looking to raise capital in the market
  • Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
  • Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
  • Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
  • Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
  • Identify growth segments and opportunities in each region within the industry.
  • Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.
Table of Contents

Table of Contents

1 Table of Contents

1 Table of Contents 2

  • 1.1 List of Tables 5
  • 1.2 List of Figures 7

2 Pharmaceuticals & Healthcare, Global, Deal Summary 10

  • 2.1 Pharmaceuticals & Healthcare, Global, Deal Analysis, March 2017 10
  • 2.2 Pharmaceuticals & Healthcare, Global, Major Deals, March 2017 11
    • 2.2.1 Valeant Pharma Raises USD2.4 Billion in Public Offering of Notes 11
    • 2.2.2 Creat Group to Acquire Biotest in Tender Offer 12
    • 2.2.3 Sanofi Enters into Co-Development Agreement with MedImmune 12
    • 2.2.4 Thermo Fisher Scientific Prices Public Offering of 1.45% Notes Due 2027 for USD530 Million 12
    • 2.2.5 Boston Scientific to Acquire Symetis for USD435 Million 13
  • 2.3 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, March 2017 14
  • 2.4 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, March 2017 15

3 Pharmaceuticals and Healthcare, Global, Deals, Summary, by Type 16

  • 3.1 Pharmaceuticals & Healthcare, Global, M&A, March 2017 16
    • 3.1.1 Top M&A Deals in March 2017 17
    • 3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals by Therapy Area, October 2016- March 2017 18
  • 3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, March 2017 19
    • 3.2.1 Top Equity Offering Deals in March 2017 20
    • 3.2.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, October 2016- March 2017 21
  • 3.3 Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital Deals, March 2017 22
    • 3.3.1 Top PE/VC Deals in March 2017 23
    • 3.3.2 Pharmaceuticals & Healthcare, Global, PE/VC by Therapy Area, March 2017 24
    • 3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, March 2017 25
    • 3.3.4 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, August 2016-March 2017 26
    • 3.3.5 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, August 2016-March 2017 27
  • 3.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, March 2017 28
  • 3.5 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, October 2016- March 2017 29
  • 3.6 Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payments and Deal Values (US$ m), March 2017 30
    • 3.6.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals by Payment Mode, March 2017 31
  • 3.7 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), October 2016- March 2017 32
  • 3.8 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Number Of Deals, October 2016- March 2017 33
  • 3.9 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Deal Values (US$ m), October 2016- March 2017 34
  • 3.10 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), October 2016- March 2017 35

4 Pharmaceuticals & Healthcare, Global, Licensing Agreements, March 2017 36

  • 4.1 Pharmaceuticals & Healthcare, Global, Licensing Agreements, March 2017 36
  • 4.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), March 2017 37
  • 4.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Total Deal Values (US$ m), October 2016- March 2017 38
  • 4.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront Payments and Milestone Payments (US$ m), October 2016- March 2017 39
  • 4.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Total Deal Values (US$ m), October 2016- March 2017 40
  • 4.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Upfront Payments and Milestone Payments (US$ m), October 2016- March 2017 42
    • 4.6.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Deal Value, March 2017 43
    • 4.6.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, March 2017 43
    • 4.6.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Total Milestone Payment, March 2017 44

5 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 45

  • 5.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, March 2017 45
    • 5.1.1 Oncology - Deals of the Month 46
  • 5.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, March 2017 48
    • 5.2.1 Central Nervous System - Deals of the Month 49
  • 5.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, March 2017 50
    • 5.3.1 Infectious Diseases - Deals of the Month 51
  • 5.4 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, March 2017 53
    • 5.4.1 Cardiovascular - Deal of the Month 54
  • 5.5 Pharmaceuticals & Healthcare, Global, Immunology Deals, March 2017 55
    • 5.5.1 Immunology - Deals of the Month 56
  • 5.6 Pharmaceuticals & Healthcare, Global, Respiratory Deals, March 2017 58
    • 5.6.1 Respiratory - Deal of the Month 59
  • 5.7 Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, March 2017 61
    • 5.7.1 Metabolic Disorders - Deal of the Month 62

6 Deal Summary by Geography 64

  • 6.1 Pharmaceuticals & Healthcare, North America Deals, March 2017 64
    • 6.1.1 North America - Deals of the Month 65
  • 6.2 Pharmaceuticals & Healthcare, Europe, Deals, March 2017 67
    • 6.2.1 Europe - Deals of the Month 68
  • 6.3 Pharmaceuticals & Healthcare, Asia-Pacific, Regional Deals, March 2017 70
    • 6.3.1 Asia-Pacific - Deals of the Month 71
  • 6.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, March 2017 72
    • 6.4.1 Rest of the World - Deals of the Month 73

7 Pharmaceuticals & Healthcare, Global, Top Financial Advisors 74

  • 7.1 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, October 2016- March 2017 74
  • 7.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, October 2016- March 2017 75

8 Further Information 76

  • 8.1 Methodology 76
  • 8.2 About GlobalData 77
  • 8.3 Contact Us 77
  • 8.4 Disclosure information 78
  • 8.5 Disclaimer 78

List of Tables

1.1 List of Tables

  • Table 1: Pharmaceuticals & Healthcare, Global, Deals Summary, Number of Deals and Deal Values (US$ m), October 2016- March 2017 11
  • Table 2: Pharmaceuticals & Healthcare, Global, Major Deals, March 2017 11
  • Table 3: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), March 2017 15
  • Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), October 2016- March 2017 17
  • Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, March 2017 17
  • Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, October 2016- March 2017 18
  • Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), October 2016- March 2017 20
  • Table 8: Pharmaceuticals & Healthcare, Global, Top Equity Offering Deals, March 2017 20
  • Table 9: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$ m), October 2016- March 2017 21
  • Table 10: Pharmaceuticals & Healthcare, Global, PE/VC, Deals Summary, Number of Deals and Deal Values (US$ m), October 2016- March 2017 23
  • Table 11: Pharmaceuticals & Healthcare, Global, Top PE/VC Deals, March 2017 23
  • Table 12: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Deals Summary, October 2016- March 2017 24
  • Table 13: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals and Deal Values (%), March 2017 26
  • Table 14: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), October 2016- March 2017 27
  • Table 15: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, October 2016- March 2017 27
  • Table 16: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), October 2016- March 2017 28
  • Table 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), October 2016- March 2017 29
  • Table 18: Pharmaceuticals & Healthcare, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), October 2016- March 2017 30
  • Table 19: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront and Milestone Payments and Deal Values (US$ m), March 2017 31
  • Table 20: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), October 2016- March 2017 32
  • Table 21: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, October 2016- March 2017 34
  • Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payment and Deal values (US$ m), October 2016- March 2017 35
  • Table 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), October 2016- March 2017 36
  • Table 24: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront and Milestone Payments and Deal Values (US$ m), October 2016- March 2017 37
  • Table 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), October 2016- March 2017 38
  • Table 26: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments (US$ m), March 2017 39
  • Table 27: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, October 2016- March 2017 41
  • Table 28: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), March 2017 42
  • Table 29: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Value, March 2017 43
  • Table 30: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Upfront Payments, March 2017 43
  • Table 31: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Milestone Payment, March 2017 44
  • Table 32: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), October 2016- March 2017 46
  • Table 33: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), October 2016- March 2017 49
  • Table 34: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Deals Summary, Number of Deals and Deal Values (US$ m), October 2016- March 2017 51
  • Table 35: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), October 2016- March 2017 54
  • Table 36: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), October 2016- March 2017 56
  • Table 37: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), October 2016- March 2017 59
  • Table 38: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), October 2016- March 2017 62
  • Table 39: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), October 2016- March 2017 64
  • Table 40: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), October 2016- March 2017 68
  • Table 41: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), October 2016- March 2017 71
  • Table 42: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), October 2016- March 2017 73
  • Table 43: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), October 2016- March 2017 74
  • Table 44: Pharmaceuticals & Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), October 2016- March 2017 75

List of Figures

1.2 List of Figures

  • Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$ m), October 2016- March 2017 10
  • Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), March 2017 14
  • Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), March 2017 15
  • Figure 4: Pharmaceuticals & Healthcare, Global, M&As, Number of Deals and Deal Values (US$ m), October 2016- March 2017 16
  • Figure 5: Pharmaceuticals & Healthcare, Global, M&As by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, October 2016- March 2017 18
  • Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), October 2016- March 2017 19
  • Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, Number of Deals and Deal Values (US$ m), October 2016- March 2017 21
  • Figure 8: Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital, Number of Deals and Deal Values (US$ m), October 2016- March 2017 22
  • Figure 9: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, October 2016- March 2017 24
  • Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals (%), March 2017 25
  • Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Deal Values (%), March 2017 25
  • Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), October 2016- March 2017 26
  • Figure 13: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), October 2016- March 2017 28
  • Figure 14: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), October 2016- March 2017 29
  • Figure 15: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), October 2016- March 2017 30
  • Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), October 2016- March 2017 32
  • Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, October 2016- March 2017 33
  • Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, October 2016- March 2017 34
  • Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), October 2016- March 2017 35
  • Figure 20: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), October 2016- March 2017 36
  • Figure 21: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), October 2016- March 2017 37
  • Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), October 2016- March 2017 38
  • Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), October 2016- March 2017 39
  • Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Number Of Deals, October 2016- March 2017 40
  • Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Deal Values (US$ m), October 2016- March 2017 40
  • Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, by Upfront and Milestone Payments and Deal Values (US$ m), March 2017 42
  • Figure 27: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), October 2016- March 2017 45
  • Figure 28: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), October 2016- March 2017 48
  • Figure 29: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Number of Deals and Deal Values (US$ m), October 2016- March 2017 50
  • Figure 30: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), October 2016- March 2017 53
  • Figure 31: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), October 2016- March 2017 55
  • Figure 32: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), October 2016- March 2017 58
  • Figure 33: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), October 2016- March 2017 61
  • Figure 34: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), October 2016- March 2017 64
  • Figure 35: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), October 2016- March 2017 67
  • Figure 36: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), October 2016- March 2017 70
  • Figure 37: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), October 2016- March 2017 72
  • Figure 38: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), October 2016- March 2017 74
  • Figure 39: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), October 2016- March 2017 75
Back to Top